louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00784069: Dermacyd Breeze (Lactic Acid) Pocket BR - Photo Evaluation
Official title: Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd Breeze Pocket BR.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Hygiene
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
First posted: 2008-11-02
Enrollment: 27
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: To demonstrate the absence of photoirritation and photosensitization potential of the product Dermacyd Breeze (Lactic Acid) Pocket BR.


Eligibility criteria: Inclusion criteria:

* Age between 18 and 60 years old;
* Phototype Skin II and III;
* Integral skin test in the region;
* Willingness in following the study procedures and to be present in the clinic at the days and scheduled time for medical evaluations and for application of occlusion;

Exclusion criteria:

* Lactation or gestation;
* Use of Antiinflammatory and/or immunosuppression drugs 15 days before the selection;
* Diseases which can cause immunity decrease, such as HIV, diabetes;
* Use of drug photosensitizer;
* History of sensitivity or irritation for topic products;
* Active cutaneous disease which can change the study results;
* History of photodermatosis active;
* Family or personal antecedent of cutaneous photoinduced neoplasias;
* Presence of a precursor lesion of cutaneous neoplasia, such as nevus melanocyte and queratoses actinium;
* Intense solar exposure in the study area;
* Use of new drugs or cosmetics during the study

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Primary outcomes:
measure: To demonstrate the absence of photoirritation and photosensitization potential of the product Dermacyd Breeze Pocket BR.
timeFrame: Throughout the study
Secondary outcomes:
Other outcomes:
Locations:
city: Sao Paulo
country: Brazil
facility: Sanofi-Aventis Administrative Office
Study officials:
affiliation: Sanofi
name: Jaderson Lima
role: STUDY_DIRECTOR
References:
Clinical trial NCT04962269: Application of DWI in Diagnosis of Prostate Cancer
Official title: Different Models of Multiple B-value DWI and Their Applications in Diagnosis of Prostate Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Prostate Cancer
Benign Prostatic Hyperplasia
Keywords: benign prostatic hyperplasia
Diffusion weighted imaging
Lead sponsor: Peking University Third Hospital
Sponsor class: OTHER
First posted: 2021-07-14
Enrollment: 103
Sex: MALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with prostatic diseases confirmed as prostate cancer or benign prostatic hyperplasia

Brief summary: This study compared the performance of different models of multiple b-value DWI in diagnosing prostate cancer.

Detailed description: Diffusion weighted imaging (DWI) plays an important role in the diagnosis and stratification of prostate cancer. Traditional DWI apply the apparent diffusion coefficient (ADC) to reflect the diffusion of tissue water, which is a parameter calculated by a monoexponential model with 2b values. In recent years, the development of multiple b-value DWI facilitates the appearance of many new mathematical models. Different models have different features, but their value of applications in prostate cancer still need to be confirmed. This study was aiming to: (1) compare the parameters derived from monoexponential model, intravoxel incoherent motion (IVIM) model and stretched exponential model between prostate cancer and benign prostatic hyperplasia; (2) compare the difference of these parameters between low-grade (Gleason score ≤ 3+4) and high-grade (Gleason score ≥ 4+3) cancer; (3) find whether these parameters derived from new models are superior to ADC derived from traditional monoexponetial model.

Eligibility criteria: Inclusion Criteria:

1. The exam including T1WI、T2WI and multiple b-value DWI.
2. Comfired by pathology as prostate cancer or benign prostatic hyperplasia in one month after the MRI exam.

Exclusion Criteria:

* 1.No Gleason score data. 2.Awful quality of imagings or artifacts affectting diagnosis. 3.No lesion larger than 0.5cm. 4.Any surgery or treatment before MRI exam. 5.Biopsy in 4 weeks before MRI exam.

Primary outcomes:
measure: pathological diagnosis
timeFrame: 2013.10-2018.6
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Peking University
name: Jianyu Liu
role: STUDY_DIRECTOR
References:
Clinical trial NCT03122769: Cardiac Uptake of Metformin, Visualized by Positron Emission Tomography
Official title: Cardiac Uptake of Metformin and Expression of Metformin Membrane Transporter Proteins in the Human Failing Myocardium
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Heart Failure, Systolic
Keywords: Metformin
Heart Failure
Organic cation transporter
Pharmacogenetics
Pharmacokinetics
Positron Emission Tomography
Lead sponsor: Aarhus University Hospital
Sponsor class: OTHER
First posted: 2017-04-21
Enrollment: 6
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: All 6 subjects allocated to the study will receive 11C-metformin intravenously.
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to evaluate if metformin is taken up into the failing myocardium. Recent experimental and epidemiological studies have shown beneficial effects of metformin on heart failure. It is unknown whether this effect is direct or indirect.

The aim of the study is to investigate if metformin is taken up in heart failure using a novel 11C-metformin tracer and positron emission tomography (PET).


Eligibility criteria: Inclusion Criteria:

* Patients with chronic heart failure, Left Ventricular Ejection Fraction \<45%
* New York Heart Association (NYHA) class I, II, III
* Relatively preserved renal function (eGFR \> 30 ml/min)
* Ability to understand the written patient information and to give informed consent
* Negative p-HCG for women of childbearing potential

Exclusion Criteria:

* Known allergy to metformin
* Age \< 18 years
* Current abuse of alcohol or drugs

Primary outcomes:
measure: Metformin uptake in the failing myocardium
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Aarhus N
country: Denmark
facility: Aarhus University Hospital, Department of Cardiology, Palle Juul-Jensens Boulevard 99
Study officials:
References:
Clinical trial NCT03096769: Ergonomics in Robotic Surgery
Official title: Ergonomics in Robotic Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Musculoskeletal Strain
Ergonomics
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2017-03-30
Enrollment: 6
Sex: ALL
Minimum age (years): 30
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: This study is designed to answer if an ergonomist can configure a daVinci robot console to improve surgeon discomfort. Adjustments to the robot console will be surgeon specific as they are tailored to their individual body type. Measurements will be taken at the time of console configuration.


Eligibility criteria: Inclusion Criteria:

* Fellowship trained, specialty board certified gynecologic surgeon.
* Robot used for hysterectomy until completion of vaginal cuff closure.

Exclusion Criteria:

- Any non-robotic method to perform hysterectomy (laparotomy, non-robotic laparoscopic, vaginal approach).

Primary outcomes:
measure: Change in Nordic Upper Body Questionnaire Score
timeFrame: Baseline, Immediately postoperative (approximately one hour)
measure: Change in Body Part Discomfort Questionnaire Score
timeFrame: Baseline, Immediately postoperative (approximately one hour)
measure: Surgical Task Load Index Score
timeFrame: Immediately postoperative (approximately one hour)
Secondary outcomes:
measure: Change in measurement of console settings (in cm)
timeFrame: Baseline, up to 1 year
measure: Change in measurement of console head angle (in degrees)
timeFrame: Baseline, up to 1 year
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: John A Occhino
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00660569: Utilization Patterns of Pulmicort in Real Life Practice
Official title: Utilization Patterns of Pulmicort HFA in Real Life Practice
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Asthma
Keywords: asthma treatment
utilization
real life practice
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2008-04-17
Enrollment: 260
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Population treated by General Practitioner, Pneumologists or Paediatricians

Brief summary: The purpose of this study is to identify the potential issues during short and mid term utilization of Pulmicort hydro fluoroaklane (HFA) pressurized metered-dose inhaler (pMDI)and describe associated factors.


Eligibility criteria: Inclusion Criteria:

* Asthmatic patients with a diagnose of at least 12 months of duration before study inclusion
* Patients previously treated with Pulmicort CFC who have changed their treatment to Pulmicort HFA

Exclusion Criteria:

* Disability that, from investigator point of view, prevent from complying the follow up schedule
* To have participated in any clinical study in the past 6 months

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Sabadell
country: Spain
facility: Research Site
state: Barcelona
city: Alcorcon
country: Spain
facility: Research Site
state: Madrid
city: Leganes
country: Spain
facility: Research Site
state: Madrid
city: San Sebastian de los Reyes
country: Spain
facility: Research Site
state: Madrid
city: Olivares
country: Spain
facility: Research Site
state: Sevilla
city: Fuentes de Ebro
country: Spain
facility: Research Site
state: Zaragoza
city: Barcelona
country: Spain
facility: Research Site
city: Madrid
country: Spain
facility: Research Site
city: Murcia
country: Spain
facility: Research Site
city: Toledo
country: Spain
facility: Research Site
Study officials:
affiliation: AstraZeneca MC SpainEpidemiologyValue Demonstration Unit
name: Javier Nuevo Rivero
role: STUDY_DIRECTOR
References:
Clinical trial NCT03321669: Impact of Diet on Capsule Endoscopy
Official title: Impact of Diet on Capsule Endoscopy Transit Time - a Pilot Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Small Bowel Disease
Lead sponsor: Hospital Britanico
Sponsor class: OTHER
First posted: 2017-10-26
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Capsule endoscopy studies are used for the diagnosis of small bowel mucosal lesions. Since capsule endoscopy depends on the small intestinal peristaltism, the food intake - especially the amount of fat ingested - after the ingestion of the capsule may have an impact on the capsule endoscopy transit time and thus its diagnostic yield. As a consequence, an open-label randomized pilot study was designed to determine wether increased dietary intake of fat after the ingestion of the capsule endoscopy may influence small intestinal transit time and thus the diagnosis of small bowel lesions.


Eligibility criteria: Inclusion Criteria:

* Adult patients undergoing capsule endoscopy study

Exclusion Criteria:

* Not being able to follow a diet with increased amount of fat

Primary outcomes:
measure: Small bowel transit time
timeFrame: 12 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Buenos Aires
country: Argentina
facility: Hospital Britanico
Study officials:
References:
Clinical trial NCT06787469: Comparison of the Clinical Performance of High Strength Hybrid Ceramic Indirect Restorations Cemented on Endodontically Treated Teeth Using Bioactive Versus Conventional Self Adhesive Resin Cements.
Official title: Clinical Performance of CAD/CAM Hard Hybrid Ceramic Overlays on Endodontically Treated Molars Using Bioactive Versus Conventional Self-Adhesive Resin Cement: Two-Year Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Endodontically Treated Molar
Keywords: Resin Cement
SHOFU
Bioactive Resin Cement
SPRG
S-PRG
Endodontically treated teeth
BeautiLink SA
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2025-01-22
Enrollment: 50
Sex: ALL
Minimum age (years): 21
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: This study will be conducted on the form of a randomized controlled, unicenter, clustered two-arm superiority trial with a 1:1 allocation.
Primary purpose: TREATMENT

Brief summary: Cementation of indirect restoration is a determinant of the success or failure of the fabricated restoration and consequentially the entire tooth. While there are numerous commercially available resin cements in the dental market, not all have been sufficiently assessed with significant follow up periods to clinically determine their success or failure. As such, this research will be conducted to elucidate if there is a viability to the cementation of indirect hybrid ceramic blocks over endodontically treated teeth using bioactive self-adhesive resin cement and determining whether it provides a clinical advantage and improved restoration serviceability in the oral cavity.


Eligibility criteria: Inclusion Criteria:

* Patient Related Criteria:
* Adult patients (age: 21-50 years) of both genders.
* Able to tolerate necessary restorative procedures.
* Willing to sign the informed consent.
* Accepts the follow-up period.

Tooth Related Criteria:

* Endodontically treated first and second permanent molars.
* Access cavities with one missing proximal wall i.e. Occluso-mesial/distal cavities
* Patients with proper oral hygiene

Exclusion Criteria:

* Endodontically treated anterior, premolar and third molar teeth
* Badly broken-down teeth
* Hopelessly carious/destructed teeth necessitating extraction
* Mobile teeth, indicating periodontal disease or trauma.
* External or internal resorption.
* Cervical carious lesions
* Medically compromised patients
* Patients with known allergies to Latex and/or resinous material

Primary outcomes:
measure: Modified USPHS Criteria
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00435669: A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)
Official title: Mass Balance, Pharmacokinetics and Metabolism of [14C]BMS-582664 Prodrug of BMS-540215, in Subjects With Advanced or Metastatic Solid Tumors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Tumors
Keywords: Advanced or metastatic solid tumors
Lead sponsor: Bristol-Myers Squibb
Sponsor class: INDUSTRY
First posted: 2007-02-15
Enrollment: 4
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this trial is to determine the mass balance, pharmacokinetics, metabolism, and routes and extent of elimination of BMS-582664


Eligibility criteria: Inclusion Criteria:

* Histologic/cytologic diagnosis of advanced or metastatic solid tumors
* ECOG 0-2
* 4/6 weeks since prior therapy

Exclusion Criteria:

* Brain metastases
* Secondary primary malignancy
* Thromboembolic disease requiring full anticoagulation within 6 months
* Inability to swallow or absorb oral therapy
* Uncontrolled hypertension

Primary outcomes:
measure: Absorption
timeFrame: Determined by PK measurement collected on Day 1 at timepoints 0 (predose) 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 18 and 24 hour. Continue daily PK collection on Day 2 to Day 10
measure: Distribution
timeFrame: Determined by PK measurement collected on Day 1 at timepoints 0 (predose) 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 18 and 24 hour. Continue daily PK collection on Day 2 to Day 10
measure: Metabolism
timeFrame: Determined by PK measurement collected on Day 1 at timepoints 0 (predose) 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 18 and 24 hour. Continue daily PK collection on Day 2 to Day 10
measure: Elimination of BMS-582664
timeFrame: Determined by PK measurement collected on Day 1 at timepoints 0 (predose) 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 18 and 24 hour. Continue daily PK collection on Day 2 to Day 10
Secondary outcomes:
measure: To assess safety and tolerability of BMS-582664 800 mg administered daily in Part B
timeFrame: at last patient last visit
Other outcomes:
Locations:
city: Cleveland
country: United States
facility: Cleveland Clinic Foundation
state: Ohio
Study officials:
affiliation: Bristol-Myers Squibb
name: Bristol-Myers Squibb
role: STUDY_DIRECTOR
References:
Clinical trial NCT00521469: A Randomized Controlled Single-Blind Study of the Effects of Instrument-Applied Spinal Manipulative Therapy on Postural Control
Official title: A Randomized Controlled Single-Blind Study of the Effects of Instrument-Applied Spinal Manipulative Therapy on Postural Control
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Disequilibrium
Keywords: Disequilibrium
Spinal Manipulation
Postural control
Lead sponsor: Logan College of Chiropractic
Sponsor class: OTHER
First posted: 2007-08-28
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: To determine the effects of instrument-applied chiropractic manipulative therapy (CMT) on postural control.


Eligibility criteria: Inclusion Criteria:

* Students, staff or faculty

Exclusion Criteria:

* No previous lower extremity injury, surgery, visual or vestibular condition that would affect balance
* Systemic illness that could have an adverse effect on balance
* Local infection, injury or other malignancy affecting the lower extremity
* any unstable joints of the lower extremity
* Any Spinal manipulation within 48 hours
* Prescription or herbal muscle stimulants, relaxants, etc. that could affect balance
* Pregnancy

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Chesterfield
country: United States
facility: Logan College of Chiropractic
state: Missouri
Study officials:
affiliation: Logan College of Chiropractic
name: Rodger Tepe, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02013869: Low Flow Anaesthesia, is There a Difference Between 2 Modern Anaesthetic Machines Using Different Gas Reservoir
Official title: Low Flow Anaesthesia; Cost-effectiveness of the Flow-I Anaesthesia Machine, a Comparison to Established Anaesthesia Delivery Unit
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: General Anaesthesia
Keywords: fresh gas flow
quality of anaesthesia
minimal alveolar concentration
Lead sponsor: Karolinska Institutet
Sponsor class: OTHER
Collaborators: name: University of California, Irvine
First posted: 2013-12-17
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: We studied the time to reach a MAC value for two fifferent anaesthetic machines, Flow-i versus Aisys looking at the time to reach 1 MAC desflurane
Primary purpose: BASIC_SCIENCE

Brief summary: To study the Flow-I breathing circle during low flow general anaesthesia, whether this non-below system has advantages reduced time to reach Et 1MAC (minimal alveolar concentration) and lower consumption of inhaled agent

Detailed description: Assessing whether there are clinical differences in anaesthetic performance between standard anaesthesia workstation including a below and the new Flow-I device without a below

Eligibility criteria: Inclusion Criteria:

ASA 1-2 patient 18 - 65 years scheduled for elective surgery

Exclusion Criteria:

ASA \> 2 heart failure COPD

Primary outcomes:
measure: Time to reach 1.5 MAC (minimal alveolar concentration) Et
timeFrame: 1 hour
Secondary outcomes:
measure: amount of inhaled agent consumed ml/min
timeFrame: 5 hours
measure: Postoperative Quality of Recovery
timeFrame: 72 hours
Other outcomes:
measure: Adequate anaesthesia
timeFrame: 5 hours
Locations:
city: Stockholm
country: Sweden
facility: Danderyds Hospital
Study officials:
affiliation: Karolinska Institutet
name: Jan g Jakobsson, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05751369: Addressing Tobacco, E-Cigarette, and Cannabis Waste
Official title: The Tobacco, E-Cigarette, and Cannabis Waste Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Knowledge, Attitudes, Practice
Lead sponsor: California State University, San Marcos
Sponsor class: OTHER
Collaborators: name: University of California, Davis
First posted: 2023-03-02
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study tests of effect of brief education and support about tobacco, e-cigarette, and cannabis waste (TECW) on knowledge, beliefs, behavior, and TECW on two college campuses.


Eligibility criteria: Inclusion Criteria:

* student at University of California, Davis or California State University San Marcs
* between the ages of 18 and 25
* taking at least one class on the main campus
* at least six months until graduation
* have a smart phone with location services enabled for apps
* regular access to a device with sufficient WiFi
* private space for three remote visits on over the next six weeks and one visit in six months
* willing to have camera on during remote visits

Exclusion Criteria:

* None

Primary outcomes:
measure: Knowledge about TECW
timeFrame: 6 weeks
Secondary outcomes:
measure: Perceived harmfulness of TECW
timeFrame: 6 weeks
measure: Belief that TEC manufacturers should be accountable for waste mitigation
timeFrame: 6 weeks
measure: Use of TECW Tracker
timeFrame: 6 weeks
measure: Readiness to engage in regulatory behavior
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Davis
country: United States
facility: University of California, Davis
state: California
city: San Marcos
country: United States
facility: California State University San Marcos
state: California
Study officials:
References: